Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies.
Location: United States, California, Palo Alto
Employees: 11-50
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | S32 | s32.com |
| 22.11.2023 | Two Sigma ... | twosigmave... |
| 14.02.2023 | Blue Ventu... | blueventur... |
Mentions in press and media 3
| Date | Title | Description |
| 13.12.2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday, Term Sheeters. Paid Content Keeping file transfers secure and simple in the cloud F... |
| 13.12.2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday, Term Sheeters. Paid Content PwC is teaching executives to lead with trust. Here’s w... |
| 12.12.2021 | Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection | Exai Bio, a next-generation liquid biopsy company, announced it has raised a $67.5 million Series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection. The financing was led ... |